List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 292 studies with search of:   "Trastuzumab"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Terminated Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Metastatic Breast
Interventions: Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®
2 Recruiting Six vs 12 Months of Transtuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil;   Drug: Granulocyte-colony stimulating growth factor;   Drug: Trastuzumab
3 Not yet recruiting A Dose Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and HER2 Positive Female Patients
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin]
4 Recruiting The Synergism Or Long Duration (SOLD) Study
Condition: Breast Neoplasms
Interventions: Drug: trastuzumab (9 weeks) + docetaxel;   Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
5 Recruiting A Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel;   Drug: trastuzumab;   Drug: trastuzumab-MCC-DM1
6 Recruiting A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone & Trastuzumab;   Drug: Docetaxel & Trastuzumab
7 Recruiting BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
8 Recruiting Trastuzumab Optimization Trial in Breast Cancer
Condition: Metastatic or Locally Advanced Breast Cancer
Intervention: Drug: trastuzumab
9 Recruiting Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Condition: Ductal Carcinoma In Situ
Intervention: Drug: Herceptin (Trastuzumab)
10 Recruiting Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-Positive Breast Cancer (Study P05048AM2)
Condition: Breast Neoplasm
Interventions: Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab;   Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel
11 Not yet recruiting Efficacy and Safety Study Evaluating IPI-504 With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Cancer of the Breast
Intervention: Drug: IPI-504 and Trastuzumab
12 Completed Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Trastuzumab;   Drug: Cisplatin
13 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: doxorubicine, cyclophosphamide, docetaxel;   Drug: doxorubicine, cyclophosphamide, trastuzumab, docetaxel;   Drug: trastuzumab, docetaxel, carboplatin
14 Completed Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Trastuzumab
15 Not yet recruiting Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles;   Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles
16 Recruiting Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Trastuzumab (Herceptin)
17 Recruiting Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
18 Active, not recruiting Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
Condition: Urologic Neoplasms
Intervention: Drug: Trastuzumab (Herceptin), Paclitaxel, Carboplatin, Gemcitabine
19 Recruiting Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
Condition: Breast Cancer
Interventions: Drug: Vorinostat;   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy or Lumpectomy;   Drug: Post surgery therapy (Trastuzumab)
20 Not yet recruiting Safety Study of AMG 386 to Treat HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Conditions: Tumors;   Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors
Interventions: Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 3 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 3 mg/kg, Capecitabine and Lapatinib

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services